FibroBiologics EBIT

The latest EBIT for FBLG is $-18M as of March 2026. That compares with $-14M in the prior-year period — down 29.4% year over year. That is above the sector sector average of $-69M. Investors often review this figure alongside FibroBiologics's historical trend and sector peers before judging valuation or financial health.

Over the past year, FBLG's EBIT moved from $-14M to $-18M — a 29.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in FibroBiologics's operating scale or balance-sheet position.

Against its sector companies, FBLG currently prints $-18M for EBIT, while the sector average sits near $-69M. That is roughly 73.4% above the sector mean. Large gaps often invite a closer look at FibroBiologics's growth, margins, and balance sheet.

A EBIT figure of $-18M for FBLG is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-69M. Explore the charts below for those layers of context.

After noting FBLG's EBIT ($-18M), review year-over-year change from $-14M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.